Graham Holdings Company Common Stock vs Sana Biotechnology Inc — how do they compare? Graham Holdings Company Common Stock trades at $1,186.01 (market cap $5.02B), while Sana Biotechnology Inc trades at $2.33 (market cap $719.96M). The key difference: Graham Holdings Company Common Stock is far larger — about 7× Sana Biotechnology Inc's market cap, and Graham Holdings Company Common Stock pays a 0.63% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Graham Holdings Company Common Stock for 0 Days and Sana Biotechnology Inc for 24 Days on average.
| GHC | SANA | |
|---|---|---|
Market Cap | $5.02B | $719.96M |
Volume | 21,118 | 4,901,517 |
Sector | Industrials | Health |
52-Week High | $1.23K | $5.92 |
52-Week Low | $949.84 | $2.33 |
Typical Hold Time | 0 Days | 24 Days |
Enterprise Value | $5.12B | $633.21M |
Dividend Yield | 0.63% | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
SANA Biotechnology trades at $2.41, down 8.02% today, with a bearish technical signal despite bullish oscillators showing oversold conditions. The company shows no revenue with substantial losses (-$244.17M net income in 2025) and negative cash flow, though analyst consensus remains strongly positive with 82% buy ratings. Recent investor conference presentations indicate active business development efforts.
The stock presents high-risk speculative potential with strong Wall Street support but faces fundamental challenges including no revenue generation and significant cash burn. Investment opportunity hinges on successful clinical developments, while risks include continued operational losses and potential dilution from financing activities.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Graham Holdings Company is a diversified holding company with operations spanning education services (Kaplan), television broadcasting (Graham Media Group), healthcare services, and manufacturing, among other businesses; it was formerly known as The Washington Post Company.
Read more on GHC →Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →